Lung function comparison between two decades in cystic fibrosis children: A single centre study.
Gloria Tridello1, Sonia Volpi1, Baroukh M Assael1
1Cystic Fibrosis Center, Verona, Italy.
Pediatric Pulmonology
|October 1, 2015
Summary
This study found improved lung function in cystic fibrosis (CF) patients diagnosed via newborn screening over two decades. These findings highlight the impact of modern CF therapies on patient outcomes.
Area of Science:
- Pulmonology
- Pediatrics
- Genetics
Background:
- Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
- Neonatal screening allows for early diagnosis and intervention.
- Therapeutic advancements have significantly impacted CF patient care.
Purpose of the Study:
- To compare pulmonary function decline in two CF patient cohorts born in different decades.
- To assess the impact of neonatal screening and evolving treatments on CF outcomes.
- To identify a potential cohort effect in CF patient lung function.
Main Methods:
- Retrospective analysis of CF patients born between 1979-1984 (Cohort 1) and 1991-1996 (Cohort 2).
- Comparison of pulmonary function decline (FEV1%, FEF 25-75%) from ages 10 to 15.
- Statistical analysis using a linear mixed model approach to evaluate cohort differences.
Main Results:
- Significant amelioration in pulmonary function decline observed in Cohort 2 compared to Cohort 1 (P < 0.001 for both FEV1% and FEF 25-75%).
- Mean absolute decrement of FEV1% was 9.2 in Cohort 1 vs. 0.6 in Cohort 2.
- Mean decrement of FEF 25-75% was 16.3 in Cohort 1 vs. 1.3 in Cohort 2.
Conclusions:
- Pulmonary function has markedly improved in young CF patients over a decade.
- This improvement correlates with the introduction of key therapies like dornase alfa, tobramycin, and hypertonic saline.
- This study provides evidence of a cohort effect in CF patients diagnosed through neonatal screening.
Related Concept Videos
01:24Cystic Fibrosis: Management
620
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
620
01:23Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
01:25Pulmonary Function Tests
1.0K
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
1.0K
01:47Lung Capacity
57.9K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
57.9K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.4K
01:26Respiratory Volumes and Capacities I
2.0K
Assessing the respiratory rate and rhythm for a complete minute is crucial for evaluating the breathing pattern. Even a minor increase in the patient's average respiratory rate, by as little as three to five breaths per minute, is an early and vital indicator of respiratory distress. Patients with a respiratory rate exceeding twenty-four breaths per minute require close monitoring to determine the physiological alterations. This careful observation is essential for prompt recognition and...
2.0K